The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes

See also Lordkipanidze M, Harrison P. Aspirin twice a day keeps new COX‐1 at bay. This issue, pp 1217–9.

[1]  C. Patrono,et al.  Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. , 2012, Blood.

[2]  O. Boutaud,et al.  Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome , 2012, Hypertension.

[3]  P. Hjemdahl,et al.  Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications , 2011, Thrombosis and Haemostasis.

[4]  M. Lordkipanidzé,et al.  Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. , 2011, International journal of cardiology.

[5]  J. Bussel,et al.  Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. , 2011, Blood.

[6]  Masafumi Ueno,et al.  Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease , 2011, Circulation. Cardiovascular interventions.

[7]  J. Dillinger,et al.  24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease , 2010, Thrombosis and Haemostasis.

[8]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[9]  I. Elalamy,et al.  Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes , 2010, International journal of hematology.

[10]  Mary Cushman,et al.  Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation , 2010, Circulation.

[11]  G. Davı̀,et al.  The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. , 2010, Blood.

[12]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[13]  Darrell R. Abernethy,et al.  Effect of Obesity on the Pharmacokinetics of Drugs in Humans , 2010, Clinical pharmacokinetics.

[14]  M. Furman,et al.  Association of Cyclooxygenase-1–Dependent and –Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization , 2009, Circulation.

[15]  G. Tognoni,et al.  Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[16]  F. Crea,et al.  COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. , 2009, European heart journal.

[17]  F. Santilli,et al.  Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". , 2009, Journal of the American College of Cardiology.

[18]  T. Morimoto,et al.  Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes , 2012 .

[19]  P. Macfarlane,et al.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease , 2008, BMJ : British Medical Journal.

[20]  David Ames,et al.  Feasibility of conducting a primary prevention trial of low‐dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study , 2008, The Medical journal of Australia.

[21]  J. Hirsh,et al.  Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[22]  P. Gurbel,et al.  The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients , 2007, Diabetes.

[23]  G. Tognoni,et al.  Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin , 2007, Journal of thrombosis and haemostasis : JTH.

[24]  R. Bobe,et al.  Platelet PMCA‐ and SERCA‐type Ca2+‐ATPase expression in diabetes: a novel signature of abnormal megakaryocytopoiesis , 2007, Journal of thrombosis and haemostasis : JTH.

[25]  Alessandro Filippi,et al.  Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins , 2007, Trials.

[26]  P. Hjemdahl,et al.  Dose- and time-dependent antiplatelet effects of aspirin , 2006, Thrombosis and Haemostasis.

[27]  Colin Baigent,et al.  Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.

[28]  A. Maree,et al.  Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. , 2005, Journal of the American College of Cardiology.

[29]  C. Patrono,et al.  Determinants of the interindividual variability in response to antiplatelet drugs , 2005, Journal of thrombosis and haemostasis : JTH.

[30]  Y. Hong,et al.  Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[31]  R. Hillman,et al.  The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. , 1992, American journal of clinical pathology.

[32]  F. Gries,et al.  Increased GPIIB/IIIA expression and altered DNA‐ploidy pattern in megakaryocytes of diabetic BB‐rats , 1992, European journal of clinical investigation.

[33]  G. Davı̀,et al.  Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. , 1989, Biochimica et biophysica acta.

[34]  G. Davı̀,et al.  Clinical pharmacology of platelet cyclooxygenase inhibition. , 1985, Circulation.

[35]  J. Maclouf,et al.  Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. , 1985, Analytical chemistry.

[36]  G. FitzGerald,et al.  Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. , 1984, The New England journal of medicine.

[37]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[38]  C. Patrono,et al.  Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. , 1980, Thrombosis research.

[39]  P. Majerus,et al.  Inhibition of platelet prostaglandin synthetase by oral aspirin. , 1978, The Journal of clinical investigation.